Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02982720
Title Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Georgetown University
Indications

cholangiocarcinoma

Therapies

Peginterferon alfa-2b + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.